Oroxylin A

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Oroxylin A 具有通过调节白血病细胞系中的 LAP/LIP/CHOP 来抑制 ATRA 诱导的 IL-6 产生的能力，这可以为 RAS 提供治疗策略。

Oroxylin A has various anti-tumor effects including apoptosis, cell cycle arrest, drug-resistant reversion. Oroxylin A possesses abilities of inhibiting the ATRA-induced IL-6 production via modulation of LAP/LIP/CHOP in leukemia cell lines, which could providing a therapeutic strategy for RAS. Oroxylin A inhibits UCP2s triggers the MPTP opening, and promotes the apoptosis in CaCo-2 cells; uncoupling protein 2 plays a key role in mitochondrial apoptotic pathway. Oroxylin A inhibits N1ICD translocating to the nucleus and binding to epithelial-mesenchymal transition-related transcription factor Snail, thus suppressing the invasion and migration of MCF-7 cells. Oroxylin A improves the sensitivity of K562/ADM cells by increasing apoptosis in leukemic cells and decreasing the expression of CXCR4 and PI3K/Akt/NF-κB pathway, and probably served as a most promising agent for CML treatment.

——

——

Baicalein 6-methyl ether | 6-Methoxybaicalein

Others

Other Targets

Others

Cancer

——

480-11-5

284.26

C16H12O5

>98% (HPLC)

DMSO : ≥ 32 mg/mL; 112.57 mM

COC1=C(C=C2C(=C1O)C(=O)C=C(O2)C3=CC=CC=C3)O

——

(-20℃)

With Ice Pack

≥ 2 years